SGLT2 inhibitor

Teladoc Health Launches Provider-Based Care for Weight Management & Prediabetes Programs

Retrieved on: 
Tuesday, April 18, 2023
Hypertension, SGLT2 inhibitor, Obesity, Teladoc Health, Prediabetes, Sodium/glucose cotransporter 2, Mental health, Diabetes, Care, NYSE, Risk, SGLT2, TDOC, Pharmaceutical industry, Nursing

PURCHASE, N.Y., April 18, 2023 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, today announced the expansion of Provider-Based Care for weight management and prediabetes programs.

Key Points: 
  • PURCHASE, N.Y., April 18, 2023 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, today announced the expansion of Provider-Based Care for weight management and prediabetes programs.
  • Provider-Based Care delivers a unique and integrated care experience for members, including access to a Teladoc Health physician for a personalized care plan, along with coaching for day-to-day guidance with actionable digital tools.
  • This whole-person approach to care is inclusive of nutrition logging and coaching, activity tracking, sleep management, and stress and mental health in-the-moment tools and virtual care.
  • The additional levels of provider oversight and care related to medications are critical within weight management, diabetes prevention programs and diabetes management, especially as new therapies like GLP-1s and SGLT2s surge in popularity.

Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting

Retrieved on: 
Wednesday, April 12, 2023
Glycated hemoglobin, LSE, VHA, Disease, Medal "For Transforming the Non-Black Earth of the RSFSR", Kidney failure, Chronic kidney disease, Diabetes, Prevalence, Austin Convention Center, SGLT2 inhibitor, EGFR, Mount Sinai, Veteran, SALT, Icahn School of Medicine at Mount Sinai, Dialysis, Kidney, Patient, Division, Wake, NKF, Risk, National Kidney Foundation, UACR, DKD, CKD, T2D, Conference, Pharmaceutical industry, Black, Nephrology, Medicine

LONDON and SALT LAKE CITY, April 12, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that two scientific presentations have been accepted at the upcoming National Kidney Foundation Spring Clinicals Conference taking place in Austin, Texas (April 11-15). The studies entitled the “Impact of KidneyIntelX testing on novel medication prescription in a diverse patient population” and “Diabetic kidney disease epidemiology in US veterans” show the importance of using KidneyIntelX bioprognosis in early stage kidney disease and diabetes patients to blunt the effects of health inequity, help guide proper drug prescription to patients in need, and support established clinical guidelines to slow or stop unnecessary progression to late stage kidney disease, kidney failure and dialysis.

Key Points: 
  • The webinar is now on-demand and available on www.kidneyintelx.com or via this link .
  • National Kidney Foundation Clinical Spring Conference Data Presentations Include:
    KidneyIntelX was recently introduced into the Wake Forest-Atrium Health System to predict progressive decline in kidney function.
  • The KidneyIntelX risk score identified those patients at highest risk which resulted in appropriately selecting SGLT2-inhibitors for the right patients.
  • The data will be showcased from April 12-14 in the Poster Hall at the Austin Convention Center and the abstract is now online at the NKF website.

New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events

Retrieved on: 
Sunday, October 2, 2022
NEJM, Gastrointestinal tract, Heart Failure Society of America, Chronic kidney disease, THE, Neuropathic pain, Gene, Poster, Growth, Intellectual property, Form 10-K, Heart failure, SGLT2 inhibitor, EGFR, Metabolism, Diabetes, U.S. Securities and Exchange Commission, The New England Journal of Medicine, Type 2 diabetes, Protein, Nasdaq, SGLT1, Cardiovascular disease, AHA, National Executive Committee of the Labour Party, Holocene, SGLT2, Death, Research, Security (finance), GLOBE, Executive Committee, American Heart Association, University, Annual report, Kidney, FACC, School, Condition subsequent, Disease, Pharmaceutical industry, Lexicon, Patient

Patients treated with sotagliflozin in the SOLOIST-WHF trial experienced fewer single as well as multiple heart failure events than those receiving placebo, said Dr. Pitt.

Key Points: 
  • Patients treated with sotagliflozin in the SOLOIST-WHF trial experienced fewer single as well as multiple heart failure events than those receiving placebo, said Dr. Pitt.
  • Thus, we conclude that sotagliflozin altered the trajectory of patients hospitalized for worsening heart failure by reducing early and recurrent heart failure events.
  • The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.
  • The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.

Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease

Retrieved on: 
Monday, August 22, 2022
Cardiovascular disease, Cardiology, Inflammation, European Society of Cardiology, Security (finance), Research, Holocene, Form 10-K, Diabetes, Gene, EGFR, Death, Protein, Kidney, Disease, Chronic kidney disease, Meal, Heart failure, NEJM, SGLT2, Myocardial infarction, American Heart Association, SGLT2 inhibitor, U.S. Securities and Exchange Commission, Manuscript, Type 2 diabetes, Trial of the century, Gastrointestinal tract, GLOBE, Nasdaq, FDA, Publication, Stroke, The New England Journal of Medicine, SGLT1, Randomness, Congress, Intellectual property, Annual report, Thrombosis, AHA, Growth, Metabolism, Neuropathic pain, Pharmaceutical industry, Patient, Lexicon

THE WOODLANDS, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of publications concluding that sotagliflozin’s differentiated dual SGLT1 and SGLT2 mechanism of action may have implications for cardiovascular disease.

Key Points: 
  • Recent Publication in the Journal Diabetes Care Evaluates Metabolic, Intestinal and Cardiovascular Effects in a Clinical Study
    THE WOODLANDS, Texas, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of publications concluding that sotagliflozins differentiated dual SGLT1 and SGLT2 mechanism of action may have implications for cardiovascular disease.
  • SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney.
  • Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease.
  • Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous Cell Therapy for Treatment of Chronic Kidney Disease

Retrieved on: 
Thursday, January 27, 2022
Forward-looking statement, SEC, Karger Publishers, CKD, THIS, Patient, Form, Prospectus, GLOBE, Glomerular filtration rate, Proxy, Adoption, NOT, U.S. Securities and Exchange Commission, Sale, Cell, Xi, Manuscript, Combination, LP, Failure, Name, Finerenone, Research, RESPECT, ALL, Standard of care, Chronic kidney disease, Business architecture, Suite, SGLT2 inhibitor, READ, American Journal, Kidney, Securities Act of 1933, Disease, SEC filing, Communication, Roy Taylor (scientist), FDA, DOI, WHEN, Risk, Population, SCS, Dialysis, ANY, EMA, THE, Injection, Pharmaceutical industry, Nephrology, Journal

The paper, titled Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design, was published online and will appear in a future print edition of the Journal (DOI: 10.1159/000520231).

Key Points: 
  • The paper, titled Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design, was published online and will appear in a future print edition of the Journal (DOI: 10.1159/000520231).
  • The study is a prospective, multicenter, randomized control, open-label Phase II clinical trial that enrolled a total of 83 subjects ages 30-80 with Type 2 diabetic kidney disease.
  • Following a kidney biopsy, subjects were randomized 1:1 to receive either active treatment with REACT or optimized standard of care.
  • ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research.

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Retrieved on: 
Tuesday, August 3, 2021
Veterinary, Research, Mental health, Infectious diseases, Clinical trials, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Anti-diabetic drugs, Boehringer Ingelheim, Empagliflozin, Boehringer, Economy of Germany, SGLT2 inhibitor, Ingelheim am Rhein, States of Germany, Germany

In July, Boehringer Ingelheim reported a breakthrough in the treatment of heart failure with empagliflozin (marketed as JARDIANCE).

Key Points: 
  • In July, Boehringer Ingelheim reported a breakthrough in the treatment of heart failure with empagliflozin (marketed as JARDIANCE).
  • Boehringer Ingelheim also made progress in the area of neuropsychiatric disorders, including two ongoing phase II trials.
  • Quantum computing holds enormous potential for pharmaceutical research and development, particularly for early research processes in which Boehringer Ingelheim has a high level of expertise.
  • Following a successful financial year 2020, Boehringer Ingelheim continued its positive trend in the first half of 2021.

KidneyIntelX™ Enables Monitoring of SGLT2 Inhibitor Therapy Response and Corresponding Risk Reduction Over Time

Retrieved on: 
Monday, June 28, 2021
Anti-diabetic drugs, Organ systems, Clinical medicine, Medical specialties, Diabetes, TIMI, Sodium/glucose cotransporter 2, SGLT2 inhibitor, Type 2 diabetes, Diabetic nephropathy, Dapagliflozin

Until now, primary care physicians have not had an optimal way to assess risk for kidney disease progression in their type 2 diabetes patients.

Key Points: 
  • Until now, primary care physicians have not had an optimal way to assess risk for kidney disease progression in their type 2 diabetes patients.
  • KidneyIntelX provides early risk stratification which allows us to optimize and target patients in early stages of kidney disease with new medications such as SGLT2i, and moreover, these data support how KidneyIntelX can help monitor these patients and their response to treatment.
  • These results will be further evaluated through a growing body of real-world evidence and clinical effectiveness data driven by the KidneyIntelX multi-institutional study network in over 6,000 patients.
  • The ability of KidneyIntelX to assess SGLT2 inhibitor response and improvements in kidney health through repeat testing is a significant step towards broader utilization of new therapeutic agents to significantly reduce the risk of kidney failure.

Lexicon Pharmaceuticals Announces Symposium at the American Diabetes Association 81st Scientific Sessions

Retrieved on: 
Friday, June 25, 2021
Solute carrier family, Branches of biology, Proteins, Hormones, Sodium-glucose transport proteins, Sodium/glucose cotransporter 2, Sodium/glucose cotransporter 1, Glucose, Insulin, Kidney, SGLT2 inhibitor, Dapagliflozin

SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney.

Key Points: 
  • SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney.
  • Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients lives.
  • Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease.
  • Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Metacrine Accelerates MET409 Clinical Development Milestone and Reports First-Quarter 2021 Results

Retrieved on: 
Thursday, May 13, 2021
Anti-diabetic drugs, SGLT2 inhibitor, FXR, Sodium/glucose cotransporter 2

b'SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today updated a key clinical development milestone and reported its first-quarter 2021 financial results.\n\xe2\x80\x9cAs I look ahead to the second half of 2021, we are nearing significant clinical development milestones for both our MET409 and MET642 programs,\xe2\x80\x9d said Preston Klassen, M.D., MHS, CEO, Metacrine.

Key Points: 
  • b'SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today updated a key clinical development milestone and reported its first-quarter 2021 financial results.\n\xe2\x80\x9cAs I look ahead to the second half of 2021, we are nearing significant clinical development milestones for both our MET409 and MET642 programs,\xe2\x80\x9d said Preston Klassen, M.D., MHS, CEO, Metacrine.
  • SGLT-2 inhibitors, in addition to affording glycemic control and cardiovascular/renal benefits, have demonstrated positive effects on liver fat reduction.
  • Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials.
  • The Company\xe2\x80\x99s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH.

Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH

Retrieved on: 
Tuesday, March 9, 2021
Health sciences, Chemical compounds, Health, SGLT2 inhibitor, Organofluorides, Clinical trial, Obeticholic acid, Gemigliptin

The companys lead FXR clinical candidate, MET409, has successfully completed a 12-week trial in patients with NASH.

Key Points: 
  • The companys lead FXR clinical candidate, MET409, has successfully completed a 12-week trial in patients with NASH.
  • The Phase 2a clinical trial is a 16-week, randomized, placebo-controlled, multi-center trial evaluating the safety, tolerability and pharmacological activity (as measured by liver fat reduction) of MET642 (3 mg and 6 mg) vs placebo.
  • MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes.
  • MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH.